Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Patient Enrollment for All-case PMS for Imusera, Telavic Making Steady Progress: MTPC
February 1, 2012
- Mochida Pharmaceutical Sees Double-Digit Growth in Apr-Dec on Growth of Epadel
January 31, 2012
- DSP to Set Up New Chemical Research Building at Osaka Research Center
January 31, 2012
- Apr-Dec Sales Drop 8.5% due to Slump of US Subsidiary: Shionogi
January 31, 2012
- Shionogi to Set Up Development Site in Europe to Accelerate Global Development
January 31, 2012
- Takeda Initiates Domestic PIII Clinical Trials for New Prostate Cancer Drug, TAK-700
January 30, 2012
- Medisa Shinyaku’s Kyushu Plant Transfers to Sawai
January 30, 2012
- US Sales of Abilify in 2011 Post $3.96 Billion: Otsuka HD
January 30, 2012
- CMIC Chairman Nakamura Keen to “Create Profit-Generating Mechanism” for Ultra-Orphan Drugs
January 27, 2012
- Sawai Refrains from Promotion of Aricept Generics due to Tough Price Competition
January 27, 2012
- Baxter of US to Begin New Global PIII Trial of Immunoglobulin for the Treatment of Alzheimer’s Disease
January 27, 2012
- Novartis Eyes Market Penetration with pNET Indication for Afinitor, Prolonged QOL for Patients
January 26, 2012
- Abbott Sets Up New Unit With MRs Specializing in CNS, Anesthetics for Luvox Transfer
January 26, 2012
- Nippon Kayaku’s Nambu Stresses Need for Collaboration between Medium-Sized Companies in Biosimilars
January 26, 2012
- Taiyo, Teva-Kowa to Establish Teva Pharma Japan in April, with 7 Branches, 29 Sales Offices Nationwide
January 26, 2012
- 301 MSs from Medipal HD Pass 18th MR Examination
January 26, 2012
- Achievement of SVR12 with DAA-only Combination Therapy Possible in Hepatitis C: BMS
January 26, 2012
- Toho HD Upwardly Revises FY2012 Earnings Forecast Expecting Boosted Sales, Profits
January 25, 2012
- Nichi-Iko, Sanofi to Jointly Develop Remicade Biosimilar
January 25, 2012
- Pfizer Japan Launches Zithromac for Intravenous Use
January 25, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…